BGI Genomics Co., Ltd. — Investor Relations & Filings
BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 董事会秘书工作细则（2025年10月） | 2025-10-23 | Chinese | |
| 投资者关系管理制度（2025年10月） | 2025-10-23 | Chinese | |
| 董事和高级管理人员所持本公司股份及其变动管理制度（2025年10月） | 2025-10-23 | Chinese | |
| 规范关联方资金往来管理制度（2025年10月） | 2025-10-23 | Chinese | |
| 董事会环境、社会和公司治理（ESG）委员会工作细则（2025年10月） | 2025-10-23 | Chinese | |
| 关于变更注册资本、修订《公司章程》及部分治理制度的公告 | 2025-10-23 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 38372741 | 董事会秘书工作细则（2025年10月） | 2025-10-23 | Chinese | ||
| 38372720 | 投资者关系管理制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372704 | 董事和高级管理人员所持本公司股份及其变动管理制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372684 | 规范关联方资金往来管理制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372648 | 董事会环境、社会和公司治理（ESG）委员会工作细则（2025年10月） | 2025-10-23 | Chinese | ||
| 38372638 | 关于变更注册资本、修订《公司章程》及部分治理制度的公告 | 2025-10-23 | Chinese | ||
| 38372620 | 关于2025年前三季度计提信用减值损失、资产减值损失和核销资产的公告 | 2025-10-23 | Chinese | ||
| 38372604 | 关于全资子公司拟与关联方联合申报科技项目暨关联交易的公告 | 2025-10-23 | Chinese | ||
| 38372562 | 关于2026年度开展外汇套期保值业务的可行性分析报告 | 2025-10-23 | Chinese | ||
| 38372551 | 互动易平台信息发布及回复内部审核制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372540 | 独立董事工作制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372519 | 对外担保管理制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372509 | 会计师事务所选聘制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372493 | 防止控股股东、实际控制人及其他关联方占用公司资金管理制度（2025年10月） | 2025-10-23 | Chinese | ||
| 38372482 | 关于2026年度开展外汇套期保值业务的公告 | 2025-10-23 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
BGI Genomics Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55655/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55655 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55655 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55655 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55655}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BGI Genomics Co., Ltd. (id: 55655)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.